JointHealth™ express June 14, 2019
EULAR News – June 14, 2019
Madrid is the host for the 20th Annual EULAR Congress of Rheumatology. More than 14,000 participants from more than 120 countries will hear from more than 500 speakers and choose from approximately 2,500 abstract presentations.
Weight loss benefits for psoriatic arthritis patients
On the first day, attendees heard a presentation on the potential for weight loss to improve outcomes in patients with psoriatic arthritis (PsA). According to Dr. Stefan Siebert of the Institute of Infection, Immunity and Inflammation at the University of Glasgow: “There are multiple sets of data that show obesity predicts who develops PsA. Our data further show that, of patients with PsA who are candidates for a biologic, those with obesity have greater disease activity.” Dr. Siebart added: “We are using all of these expensive drugs, but I think there is now a need to also focus on lifestyle interventions, in addition to drug therapy, to reduce disease activity and improve outcomes in PsA.”
Arthritis Consumer Experts (ACE) has multiple resources to help patients learn more about the benefits of a weight loss program, nutrition and exercise. All of these programs have been shown to substantially reduce the burden of joint disease in addition to the other health advantages of losing weight and eating well. To learn more, please visit the following resources on the ACE page:
JointHealth™ Education is specifically designed for the person recently diagnosed with arthritis or living with it for a while. This education program is based on the latest research and helps patients go from being a “student” of arthritis to a full-fledged “graduate” and helps them become a leader of their health care team.
Click here to receive an email alert when the JHEd: PsA course goes live. You can sign up for our other JHEd courses here: https://info.jointhealth.org/jhed-landing-page.
Treat to target in axial spondyloarthritis (axSpA)
Treat to target is an emerging management strategy in axial spondyloarthritis. This type of disease management is well established with patients with rheumatoid arthritis and psoriatic arthritis where you have a very specific target that you want to achieve. Whether or not the approach can also work in axSpA is open to debate. One of the issues is determining what should be measured and what is the appropriate target? At a Clinical Science Session at EULAR, Dr. Pedro Machado of University College London said studies have shown that “achieving inactive disease through treat to target strategies may improve structural outcomes and stop the development of radiographic damage of the spine.” Dr. Machado added that studies show that achieving inactive disease may also help to improve patients’ functional outcomes and quality of life.
Have you been diagnosed with ankylosing spondylitis (AS) or do you know someone who is living with it? ACE will be launching a new course in its JointHealth™ Education program focusing on AS. The course will help you learn about the disease, its treatment and how to have a positive, informed conversation with your rheumatologist of other members of your healthcare team.
JointHealth™ Education is specifically designed for the person recently diagnosed with arthritis or living with it for a while. This education program is based on the latest research and helps patients go from being a “student” of arthritis to a full-fledged “graduate” and helps them become a leader of their health care team.
Click here to receive an email alert when the JHEd: AS course goes live. You can sign up for our other JHEd courses here: https://info.jointhealth.org/jhed-landing-page.
EULAR News – June 14, 2019
Madrid is the host for the 20th Annual EULAR Congress of Rheumatology. More than 14,000 participants from more than 120 countries will hear from more than 500 speakers and choose from approximately 2,500 abstract presentations.
Weight loss benefits for psoriatic arthritis patients
On the first day, attendees heard a presentation on the potential for weight loss to improve outcomes in patients with psoriatic arthritis (PsA). According to Dr. Stefan Siebert of the Institute of Infection, Immunity and Inflammation at the University of Glasgow: “There are multiple sets of data that show obesity predicts who develops PsA. Our data further show that, of patients with PsA who are candidates for a biologic, those with obesity have greater disease activity.” Dr. Siebart added: “We are using all of these expensive drugs, but I think there is now a need to also focus on lifestyle interventions, in addition to drug therapy, to reduce disease activity and improve outcomes in PsA.”
Arthritis Consumer Experts (ACE) has multiple resources to help patients learn more about the benefits of a weight loss program, nutrition and exercise. All of these programs have been shown to substantially reduce the burden of joint disease in addition to the other health advantages of losing weight and eating well. To learn more, please visit the following resources on the ACE page:
- Diet and Nutrition
- Exercise and Arthritis Podcast with Dr. Linda Li
- JointHealth™ insight – Having summer fun with arthritis
- JointHealth™ insight – Exercise and good nutrition
JointHealth™ Education is specifically designed for the person recently diagnosed with arthritis or living with it for a while. This education program is based on the latest research and helps patients go from being a “student” of arthritis to a full-fledged “graduate” and helps them become a leader of their health care team.
Click here to receive an email alert when the JHEd: PsA course goes live. You can sign up for our other JHEd courses here: https://info.jointhealth.org/jhed-landing-page.
Treat to target in axial spondyloarthritis (axSpA)
Treat to target is an emerging management strategy in axial spondyloarthritis. This type of disease management is well established with patients with rheumatoid arthritis and psoriatic arthritis where you have a very specific target that you want to achieve. Whether or not the approach can also work in axSpA is open to debate. One of the issues is determining what should be measured and what is the appropriate target? At a Clinical Science Session at EULAR, Dr. Pedro Machado of University College London said studies have shown that “achieving inactive disease through treat to target strategies may improve structural outcomes and stop the development of radiographic damage of the spine.” Dr. Machado added that studies show that achieving inactive disease may also help to improve patients’ functional outcomes and quality of life.
Have you been diagnosed with ankylosing spondylitis (AS) or do you know someone who is living with it? ACE will be launching a new course in its JointHealth™ Education program focusing on AS. The course will help you learn about the disease, its treatment and how to have a positive, informed conversation with your rheumatologist of other members of your healthcare team.
JointHealth™ Education is specifically designed for the person recently diagnosed with arthritis or living with it for a while. This education program is based on the latest research and helps patients go from being a “student” of arthritis to a full-fledged “graduate” and helps them become a leader of their health care team.
Click here to receive an email alert when the JHEd: AS course goes live. You can sign up for our other JHEd courses here: https://info.jointhealth.org/jhed-landing-page.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.